TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of “Moderate Buy” from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $126.70.

Several research firms have issued reports on TMDX. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Piper Sandler reiterated an “overweight” rating and set a $125.00 price objective (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Oppenheimer increased their price objective on TransMedics Group from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, April 23rd.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $123.34 on Friday. The business has a fifty day simple moving average of $88.46 and a 200 day simple moving average of $77.00. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of 131.21 and a beta of 1.91. TransMedics Group has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.35 earnings per share. Sell-side analysts expect that TransMedics Group will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the sale, the director now owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares during the period. CWM LLC increased its position in TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after purchasing an additional 155 shares during the period. Campbell Newman Asset Management Inc. increased its position in TransMedics Group by 1.4% in the first quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company’s stock worth $782,000 after purchasing an additional 166 shares during the period. Arizona State Retirement System increased its position in TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock worth $603,000 after purchasing an additional 184 shares during the period. Finally, Hager Investment Management Services LLC increased its position in TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock worth $50,000 after purchasing an additional 205 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.